2022
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2022, 1-10. DOI: 10.1002/9781119000822.hfcm083.pub2.Peer-Reviewed Original ResearchPeptide receptor radiotherapyMultiple endocrine neoplasiaDiffuse neuroendocrine systemClinical featuresHepatic metastasesNeuroendocrine tumorsGastroenteropancreatic systemNeuroendocrine systemInformed clinical careUnique clinical syndromeOngoing clinical trialsAbsence of symptomsCancer registry dataUnexplained incidenceReceptor radiotherapyClinical presentationRandomized trialsTherapeutic optionsClinical syndromeMultiple myelomaSomatostatin analoguesSpecific therapyRecent trialsSurvival resultsClinical trials
2010
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors
Boudreaux J, Klimstra D, Hassan M, Woltering E, Jensen R, Goldsmith S, Nutting C, Bushnell D, Caplin M, Yao J. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas 2010, 39: 753-766. PMID: 20664473, DOI: 10.1097/mpa.0b013e3181ebb2a5.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsCarcinoid syndromeManagement of carcinoid syndromeWell-differentiated neuroendocrine tumorsManagement of neuroendocrine tumorsOctreotide long-acting releaseLiver-directed therapiesPeptide receptor radiotherapyMidgut neuroendocrine tumorsPhase 3 studyVascular endothelial growth factorLong-acting releaseClassical carcinoid syndromeEndothelial growth factorDelay disease progressionMidgut carcinoidsSurgical debulkingSomatostatin analogsAdvanced diseaseNonspecific symptomsImprove quality of lifeConsensus guidelinesPrimary siteDisease progressionSmall bowel
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply